SCHEMBL7948476

SCHEMBL7948476

CC(C)C[C@@H](NS(=O)(=O)c1ccc2ccccc2c1)C(=O)NO

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LARS1 Q9P2J5 1/20 0.62
ADAM17 P78536 2/20 0.59
F2 P00734 1/20 0.53
MMP2 P08253 3/20 0.50
MMP9 P14780 3/20 0.50
SLC1A3 P43003 1/20 0.50
SLC1A2 P43004 1/20 0.50
SLC1A1 P43005 1/20 0.50
CTSL P07711 6/20 0.49
CTSS P25774 6/20 0.49
CTSK P43235 6/20 0.49
CTSB P07858 3/20 0.49
MMP1 P03956 2/20 0.49
MMP3 P08254 1/20 0.49
MMP7 P09237 1/20 0.49
MMP13 P45452 1/20 0.49
L3MBTL1 Q9Y468 1/20 0.49
KDM4E B2RXH2 1/20 0.48
MMP14 P50281 1/20 0.48
CAPN1 P07384 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1770896 1.00 LARS1 (0.62) LARS1ADAM17F2MMP2MMP9
SCHEMBL15251693 0.88 KDM4E (0.61) LARS1ADAM17F2MMP2MMP9
SCHEMBL5138976 0.88 KDM4E (0.61) LARS1ADAM17F2MMP2MMP9
SCHEMBL5138984 0.88 KDM4E (0.61) LARS1ADAM17F2MMP2MMP9
SCHEMBL4926926 0.87 ADAM17 (0.53) LARS1ADAM17F2MMP2MMP9
SCHEMBL14025840 0.87 ADAM17 (0.53) LARS1ADAM17F2MMP2MMP9
SCHEMBL1770524 0.86 LARS1 (0.58) LARS1ADAM17F2SLC1A3SLC1A2
SCHEMBL1770779 0.86 LARS1 (0.58) LARS1ADAM17F2SLC1A3SLC1A2
SCHEMBL4925885 0.86 SLC1A3 (0.54) LARS1ADAM17F2MMP2MMP9
SCHEMBL4925888 0.86 SLC1A3 (0.54) LARS1ADAM17F2MMP2MMP9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8841291-B2 Selective hydroxamic acid based MMP-12 and MMP-13 inhibitors NOVARTIS AG (CH) 2014-09-23 US disclosed
US-20140031399-A1 SELECTIVE HYDROXAMIC ACID BASED MMP-12 AND MMP-13 INHIBITORS NOVARTIS AG (CH) 2014-01-30 US disclosed
US-20110112076-A1 SELECTIVE HYDROXAMIC ACID BASED MMP-12 AND MMP-13 INHIBITORS NOVARTIS AG (CH) 2011-05-12 US disclosed
WO-2010007027-A1 SELECTIVE HYDROXAMIC ACID BASED MMP-12 AND MMP-13 INHIBITORS NOVARTIS AG (CH) 2010-01-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110112076-A1 SELECTIVE HYDROXAMIC ACID BASED MMP-12 AND MMP-13 INHIBITORS MMP13, MMP11, MMP14 LARS1 4766/4885ADAM17 26/4885F2 674/4885
US-20140031399-A1 SELECTIVE HYDROXAMIC ACID BASED MMP-12 AND MMP-13 INHIBITORS MMP13, MMP11, MMP14 LARS1 4775/4885ADAM17 26/4885F2 636/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.